SR-717 NEW
| Price | $75 | $124 | $197 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: SR-717 | CAS No.: 2375421-09-1 |
| Purity: 99.79% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | SR-717 |
| Description | SR-717 is a cGAMP analog, a non-nucleoside STING agonist that induces a "closed" activation conformation of STING. SR-717 has antitumor activity and promotes activation of immune cells and cross-presentation of antigens. |
| In vitro | METHODS: Macrophage THP1 were treated with SR-717 (3.6 μM) for 10 min-6 h. The expression levels of target proteins were detected using Western Blot. RESULTS: SR-717 activates p-STING, and its downstream p-TBK1, p-IRF3, p-p65, p-STAT1 and p-STAT3. [1] METHODS: Primary human peripheral blood mononuclear cell PBMCs were treated with SR-717 (10 μM) for 2-6 h. Gene expression levels were detected using RT-qPCR. RESULTS: SR-717 stimulated the activation of IFNB1, CXCL10 and IL6. [1] |
| In vivo | METHODS: To test the antitumor activity in vivo, SR-717 (30 mg/kg) was injected intraperitoneally into WT or Stinggt/gt C57BL/6 mice bearing mouse cutaneous melanoma tumor B16.F10 once daily for seven days. RESULTS: SR-717 inhibited tumor growth as well as prolonged the survival time of mice with rhabdomyosarcoma. The antitumor effect of SR-717 showed an enforced dependence on STING expression, and a lack of activity was observed in Stinggt/gt mice. [1] METHODS: To assay antitumor activity in vivo, SR-717 (10 mg/kg) was administered intravenously three times every two days to C57BL/6 mice harboring mouse cutaneous melanin tumor B16.F10. RESULTS: SR-717 has anti-tumor activity in vivo and prolongs survival. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 25 mg/mL (71.19 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2.5 mg/mL (7.12 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. |
| Keywords | immunity | MPYS | MITA | inhibit | SR-717 | ISG-THP1 | Inhibitor | mimetic | TMEM173 | STING | cGAMP | SR717 | THP1 | antitumor | SR 717 | ERIS | PD-L1 | Stimulator of Interferon Genes |
| Inhibitors Related | ChX710 | SN-008 | Vadimezan | Dazostinag disodium | diABZI STING agonist-1 | C-176 | Cridanimod | CCCP | diABZI STING agonist-1 trihydrochloride | MSA-2 | STING activator Compound 53 | C-178 |
| Related Compound Libraries | Bioactive Compound Library | NO PAINS Compound Library | Immuno-Oncology Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $40.00/1Box |
zhuzhou dingcheng meihei comestic co.,ltd
|
2024-05-29 | ||
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/25KG |
VIP5Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2023-09-11 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY